Neridronic acid - USA

PGR decision: Jul. 28, 2020

AIA Review #	Filing Date	Institution Date	Petitioner	Patent	Respondent	Final Written Decision
PGR2019-00026	03/01/2019	07/30/2019	Grunenthal GmbH	9,931,352	Antecip Bioventures	All Claims Unpatentable
PGR2019-00027	03/01/2019	07/30/2019	Grunenthal GmbH	10,039,774	Antecip Bioventures	All Claims Unpatentable
PGR2019-00028	01/03/2019	08/20/2019	Grunenthal GmbH	10,052,338	Antecip Bioventures	All Claims Unpatentable

US  9,931,352 (ANTECIP BIOVENTURES II LLC): Non-OB

1. A method of treating hyperalgesia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from hyperalgesia associated with complex regional pain syndrome.

17. A method of treating edema associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from edema associated with complex regional pain syndrome.

US  10,039,774 (ANTECIP BIOVENTURES II LLC): Non-OB

1. A method of treating changes in skin blood flow associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from changes in skin blood flow associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).

16. A method of treating abnormal sudomotor activity associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from abnormal sudomotor activity associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).

US  10,052,338 (ANTECIP BIOVENTURES II LLC): Non-OB

1. A method of treating allodynia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from allodynia associated with complex regional pain syndrome.

17. A method of treating autonomic motor change associated with complex regional pain syndrome (CRPS), comprising administering neridronic acid in a salt form or an acid form to a human being suffering from autonomic motor change associated with CRPS.